Switch theme
Sign up to access all valuation multiples
bioXXmed AG is an investment and holding company in the technology sector. It originated from CytoTools GmbH, a successful German technology enterprise from the pharmaceuticals and medical products field.
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
bioXXmed has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, bioXXmed achieved revenue of $19K and an EBITDA of -$0.8M.
bioXXmed expects next 12-month revenue of XXX and NTM EBITDA of XXX
See bioXXmed valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $13K | $19K | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$0.8M | -$0.8M | XXX | XXX | XXX |
| EBITDA Margin | -6400% | -4519% | XXX | XXX | XXX |
| Net Profit | -$4.4M | -$0.9M | XXX | XXX | XXX |
| Net Margin | -33180% | -4768% | XXX | XXX | XXX |
| Net Debt | $0.1M | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, bioXXmed's stock price is EUR 1 (or $1).
bioXXmed has current market cap of EUR 0.7M (or $0.7M), and EV of EUR 0.6M (or $0.6M).
See bioXXmed trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $0.6M | $0.7M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, bioXXmed has market cap of $0.7M and EV of $0.6M.
bioXXmed's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate bioXXmed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for bioXXmed and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $0.6M | XXX | XXX | XXX |
| EV/Revenue | 34.0x | XXX | XXX | XXX |
| EV/EBITDA | -0.8x | XXX | XXX | XXX |
| P/E | -0.0x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -0.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpbioXXmed's NTM/LTM revenue growth is n/a
bioXXmed's revenue per employee for the last fiscal year averaged $19K, while opex per employee averaged $0.9M for the same period.
Over next 12 months, bioXXmed's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate bioXXmed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for bioXXmed and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 42% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -4519% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 0% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $19K | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.9M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 4962% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
bioXXmed acquired XXX companies to date.
Last acquisition by bioXXmed was XXXXXXXX, XXXXX XXXXX XXXXXX . bioXXmed acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was bioXXmed founded? | bioXXmed was founded in 2000. |
| Where is bioXXmed headquartered? | bioXXmed is headquartered in Germany. |
| How many employees does bioXXmed have? | As of today, bioXXmed has 1 employees. |
| Is bioXXmed publicy listed? | Yes, bioXXmed is a public company listed on FRA. |
| What is the stock symbol of bioXXmed? | bioXXmed trades under T5O0 ticker. |
| When did bioXXmed go public? | bioXXmed went public in 2007. |
| Who are competitors of bioXXmed? | Similar companies to bioXXmed include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of bioXXmed? | bioXXmed's current market cap is $0.7M |
| What is the current revenue growth of bioXXmed? | bioXXmed revenue growth between 2023 and 2024 was 42%. |
| Is bioXXmed profitable? | Yes, bioXXmed is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
